Hutchison China Submits New Cancer Drug Application

Hutchison China Meditech Ltd. (HCM.LN) said Monday that it has submitted a new drug application to China Food and Drug Administration for cancer treatment drug fruquintinib.

The pharmaceutical company added that the submission has triggered a milestone payment of 30.8 million Chinese yuan ($4.5 million) from Lilly (LLY).

Continue Reading Below

Hutchison China Meditech is majority owned by CK Hutchison Holdings Ltd (0001.HK).

Write to Tapan Panchal at

(END) Dow Jones Newswires

June 12, 2017 02:42 ET (06:42 GMT)